For research use only. Not for therapeutic Use.
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism[1][2].
SBC-115076 (4 mg/kg; s.c.; daily for 3 weeks) reduces obesity and dyslipidemia, as well as improves insulin sensitivity in HFD-fed rats[1].
| Catalog Number | I003726 |
| CAS Number | 489415-96-5 |
| Synonyms | (4E)-4-[hydroxy-(3-methyl-4-phenylmethoxyphenyl)methylidene]-1-(3-morpholin-4-ylpropyl)-5-pyridin-4-ylpyrrolidine-2,3-dione |
| Molecular Formula | C31H33N3O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C31H33N3O5/c1-22-20-25(8-9-26(22)39-21-23-6-3-2-4-7-23)29(35)27-28(24-10-12-32-13-11-24)34(31(37)30(27)36)15-5-14-33-16-18-38-19-17-33/h2-4,6-13,20,28,35H,5,14-19,21H2,1H3/b29-27+ |
| InChIKey | VVYIXKBHQQSREP-ORIPQNMZSA-N |
| SMILES | CC1=C(C=CC(=C1)C(=C2C(N(C(=O)C2=O)CCCN3CCOCC3)C4=CC=NC=C4)O)OCC5=CC=CC=C5 |
| Reference | [1]. Chanisa Thonusin, et al. The comparative effects of high dose atorvastatin and proprotein convertase subtilisin/kexin type 9 inhibitor on the mitochondria of oxidative muscle fibers in obese-insulin resistant female rats. Toxicol Appl Pharmacol. 2019 Nov 1;382:114741. [2]. Wiciński M, et al. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J. 2017;8(4):391-402. Published 2017 Aug 14. |
